Jaguar health to report phase 3 ontarget trial results for its cancer supportive care drug crofelemer on july 23rd and hold investor webcast that morning

Webcast on tuesday, july 23rd at 8:30 am eastern will include updates on jaguar's cancer supportive care portfolio, including participation from jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (ctd) and oral mucositis; click here to register for webcast jaguar expands make cancer less shitty (mcls) patient advocacy program to incorporate select group of mcls ambassadors - cancer survivors who understand the realities of cancer and are no longer willing to accept debilitating side effects of cancer treatments as an acceptable trade-off for survival cancer patients with diarrhea are 40% more likely to discontinue their therapy; oral mucositis affects up to 40% of patients undergoing chemotherapy and approximately 90% of those receiving chemoradiation for head and neck cancers, with more than one-third of patients discontinuing cancer treatment because of the condition san francisco, ca / accesswire / july 18, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced that it will hold an investor webcast on tuesday, july 23, 2024 at 8:30 am eastern to review results for the company's pivotal phase 3 ontarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. a press release announcing the results will be issued that morning, prior to the webcast.
JAGX Ratings Summary
JAGX Quant Ranking